SecBot SecBot

SION

Sionna Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0002036042 Biotech & Drug Discovery
$3.33 −0.10 (−2.92%)
Nov 13 4:00 PM ET · prev $3.43
Market cap
$155.2M
Micro cap
Consensus
Hold
35% Buy or better · 17 analysts
Median target
🔒 Subscribers only
1 year
−91.7%
from $39.93 · Nov 17
30 days
−17.0%
from $4.01
52-week range
$3.28–51.04
−93% from high · low Nov 5
Avg volume 20D
884.8K
shares / day
Short interest
4.21M
≈9.3% of shares · +14.6%
Days to cover
4.1
at average volume
Insider net
−$118.5M
0 buyers · 4 sellers · since Mar 5
New fund stakes
0
Q3 2026 13F · 3 exits
Filing reports
20
analyzed by SecBot
SecBot read BEARISH 6 reports · 90 days
Balance 2 bearish · 0 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/6

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $118.5M.

  • InstitutionsBULLISH

    Q3 2026: 23 added (0 new), 13 trimmed or exited.

  • AnalystsMIXED

    6 of 17 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +14.6% to 4.21M shares. 4.1 days to cover, ≈9.3% of shares.

  • TrendDOWNTREND

    32% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
3
exits
FundMoveSharesValue
BlackRock, Inc.ADD2,675,216$14.1M
Aberdeen Group plcDOUBLED1,343,137$7.1M
Walleye Capital LLCDOUBLED453,319$2.4M
MARSHALL WACE, LLPDOUBLED444,016$2.3M
STATE STREET CORPTRIM377,179$2.0M
MORGAN STANLEYDOUBLED303,883$1.6M
VANGUARD PORTFOLIO MANAGEMENT LLCADD299,620$1.6M
BNP PARIBAS FINANCIAL MARKETSDOUBLED262,736$1.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Hold 35% rate it Buy or better
Strong Buy2Buy4Hold11Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Sep 15, 2026Wedbush
MAINTAIN
MAINTAINNeutral
Aug 11, 2026Guggenheim
DOWNGRADE
DOWNGRADENeutral
Aug 11, 2026Wedbush
DOWNGRADE
DOWNGRADENeutral
Aug 10, 2026BTIG
DOWNGRADE
DOWNGRADENeutral
Aug 7, 2026Guggenheim
MAINTAIN
MAINTAINBuy
May 26, 2026Citizens
REITERATE
REITERATEMarket Outperform

Insider ledger

Form 4
$0
bought · 0 insiders
$118.5M
sold · 4 insiders
DateInsiderTypeValue
Sep 17, 2026
Cloonan Michael
President & CEO
Sep 17, 2026
TO ISSUER436,100 sh
Sep 17, 2026
Fitzpatrick Jennifer
CLO and Head of Program Mgmt.
Sep 17, 2026
AWARD28,133 sh
Sep 17, 2026
Fitzpatrick Jennifer
CLO and Head of Program Mgmt.
Sep 17, 2026
AWARD28,132 sh
Sep 17, 2026
Fitzpatrick Jennifer
CLO and Head of Program Mgmt.
Sep 17, 2026
TO ISSUER103,140 sh
Sep 17, 2026
McKee Charlotte
CMO and Head of R&D
Sep 17, 2026
AWARD50,000 sh
Sep 17, 2026
Ridloff Elena
CFO and CBO
Sep 17, 2026
AWARD165,440 sh
Sep 17, 2026
Ridloff Elena
CFO and CBO
Sep 17, 2026
TO ISSUER165,440 sh
Sep 17, 2026
McKee Charlotte
CMO and Head of R&D
Sep 17, 2026
AWARD155,700 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.52-$0.72–-$0.41-19.1%$0.00
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
4,212,186
shares short
+14.6%
vs prior settlement
4.1
days to cover
≈9.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 11, 2026 Earnings calendar
SION Q3 2026 Earnings Scheduled · 2026-11-11
Nov 10, 2026 SEC
Sionna reported a Q3 2026 net loss of $32.4M ($0.72 per share), wider than the $20.3M loss a year ago, and ended the…
PRESS-RELEASE · Impact 5/10
Nov 9, 2026 SEC
Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC disclosed a 5.8% passive stake in Sionna Therapeutics…
SC 13G · Impact 3/10
Nov 3, 2026 SEC
Three institutional investors added to their SION positions in Q3 2026, but the aggregate net dollar change was…
INST-CLUSTER · Impact 2/10
Sep 30, 2026 Inst.
BlackRock, Inc. · ADD
2,675,216 shares ($14.1M)
Sep 30, 2026 Inst.
Aberdeen Group plc · DOUBLED
1,343,137 shares ($7.1M)
Sep 17, 2026 Insider
Cloonan Michael disposed of 436,100 shares
President & CEO
Sep 17, 2026 Insider
Fitzpatrick Jennifer was granted 28,133 shares
CLO and Head of Program Mgmt.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent
Nov 11, 2026
Earnings date
SION Q3 2026 Earnings Scheduled · 2026-11-11
Nov 10, 2026
Earnings
Sionna Therapeutics Reports Third Quarter 2026 Financial Results
Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027
Nov 6, 2026
Earnings date
SION Q3 2026 Earnings Scheduled · 2026-11-06
Nov 2, 2026
Press release
Sionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences
WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission…
Sep 24, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the…

SecBot reports

20 filings · 2 press releases · 0 bullish · 9 bearish · 1 mixed · 10 neutral
All SION filing & press-release reports (22)